Rae R. Matsumoto, Ph.D.
Associate Dean for Research and Graduate Programs
Dr. Matsumoto is the Associate Dean for Research and Graduate Programs in the School of Pharmacy at West Virginia University. She is a broadly trained scientist, with a well funded research program in neuropharmacology. Dr. Matsumoto obtained her Ph.D. in psychology at Brown University where her primary research interest was, and continues to deal with the effects of drugs on the brain. Dr. Matsumoto subsequently received post-doctoral training in biochemistry and physiology at Brown and Northwestern Universities. She then served as an Assistant Professor of Neurology at the University of California Irvine, and Co-Director of its Parkinson’s and Movement Disorders Program. In this role, Dr. Matsumoto was responsible for coordinating all of the basic science research activities of the unit, including the training of clinicians, fellows and students and the development of novel translational research programs. In 1996, Dr. Matsumoto moved to the University of Oklahoma Health Sciences Center in the College of Pharmacy, where her research focused on medications development for the treatment of drug abuse. She moved up the ranks to become an Edith Gaylord Harper Presidential Professor, and also held an adjunct appointment in the Department of Psychiatry. In addition, she served as the Associate Director of the Oklahoma Center for Neuroscience, where her duties included running the graduate program, and coordinating community outreach and educational activities. In 2004, Dr. Matsumoto moved to the University of Mississippi, where she served as the Director of the Center for Research Excellence in Natural Products Neuroscience after leveraging the school’s first COBRE grant. She moved to West Virginia in 2008, where she maintains an active research program, and continues her commitment to education and service.
Northwestern University Medical School, Department of Physiology, Chicago, IL
Brown University, Section of Biochemistry and Department of Psychology, Providence, RI
Brown University, Department of Psychology, Providence, RI
Creighton University, Omaha, NE (majors: biology and psychology, minor: chemistry)
Dr. Matsumoto’s laboratory uses a multidisciplinary approach to evaluate the effects of drugs on the brain. Much of her current research focuses on the development of new drugs for the treatment of neurological and psychiatric disorders.
Currently, there are no effective treatments for cocaine overdose and addiction, which exacerbates a major health and societal problem. Recently, Dr. Matsumoto’s research team developed new classes of drugs with powerful anti-cocaine actions in animals. Further testing has revealed that these drugs also combat other psychostimulants such as methamphetamine and MDMA (Ecstasy). Much of the current research in her laboratory is now focused on optimizing these compounds, and identifying the cellular and molecular mechanisms through which they exert their beneficial actions.
Depression affects about 20% of Americans. It is the leading cause of disability and costs the U.S. approximately $44 billion in loss of productivity each year. Despite recent advances in antidepressant therapy, it takes several weeks before existing medications are effective and about 30% of patients still do not respond. Dr. Matsumoto’s research group has recently developed and characterized a new class of compounds that changes animal behavior and neuronal structure and function in ways that predict favorable antidepressant potential. By targeting new mechanisms of action, these compounds are expected to help individuals who do not respond to existing medications, and to produce their therapeutic effects sooner.
The primary source of funding in Dr. Matsumoto’s laboratory is the National Institutes of Health (NIH). Since 1994, Dr. Matsumoto has received continuous research support through the following NIH institutes: National Center for Research Resources (NCRR), National Institute on Drug Abuse (NIDA), National Institutes of Mental Health (NIMH).
Synthesis and evaluation of sigma-active cocaine antagonists, R01, principal investigator (NIDA/NIH)
Novel pharmacologic interventions for drugs of abuse, R01 subcontract, principal investigator (NIDA/NIH)
Opioids with delta antagonist and mu agonist activity, R01 subcontract, principal investigator (NIDA/NIH)
Integrative training in the behavioral and biomedical sciences, T32, preceptor (NIGMS/NIH)
Recent (last five years, not listed above)
Synthesis and evaluation of sigma-active cocaine antagonists, ARRA supplement for summer student research, principal investigator (NIDA/NIH)
Synthesis and evaluation of sigma-active cocaine antagonists, ARRA supplement for equipment, principal investigator (NIDA/NIH)
Sigma ligands for the treatment of cocaine overdose, R01, principal investigator (NIDA/NIH)
Cocaine, sigma receptors and fra-2, R21, principal investigator (NIDA/NIH)
Antidepressants and sigma receptors, principal investigator (WVU Research Development Grant)
Center for Research Excellence in Natural Products Neuroscience, P20, principal investigator (NCRR/NIH)
Radioligand binding and functional assays (for screening compounds)
Rodent behavioral and physiological measurements (eg. locomotor activity, forced swim test, place conditioning, open field, elevated plus maze, tail flick, hot plate, core body temperature, video tracking)
Molecular biology (eg. Western blots, real time PCR, microarray, ELISA)
Histology (eg. immunohistochemistry, Nissl stains)
Most recent publications from the Matsumoto lab.
Kaushal, N., Elliott, M., Robson, M. J., Iyer, A. K. V., Rojanasakul, Y., Coop, A. and Matsumoto, R. R. AC927, a ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Molecular Pharmacology, Accepted for publication.
Robson, M. J., Noorbakhsh, B., Seminerio, M. J. and Matsumoto, R. R. Sigma-1 receptors: Potential targets for the treatment of substance abuse disorders. Current Pharmaceutical Design, Accepted for publication.
Fishback, J. A., Mesangeau, C., Poupaert, J. H., McCurdy, C. R. and Matsumoto, R. R. (2011) Synthesis and characterization of [3H]-SN56, a novel radioligand for the 1 receptor. European Journal of Pharmacology 653: 1-7. (PMID: 21130085)
Kaushal, N. and Matsumoto, R. R. (2011) Role of sigma receptors in methamphetamine-induced neurotoxicity. Current Neuropharmacology 9: 54-57. (PMID: 21886562)
Kaushal, N, Robson, M. J., Vinnakota, H., Narayanan, S., Avery, B. A., McCurdy, C. R. and Matsumoto, R. R. (2011) Pharmacological evaluation of 6-acetyl-3-(4-(4-(4-florophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS Journal 13: 336-346. (PMID: 21494909)
Kaushal, N., Seminerio, M. J., Shakih, J., Medina, M. A., Mesangeau, C., McCurdy, C. R. and Matsumoto, R. R. (2011) CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology 61: 992-1000. (PMID: 21762711)
Matsumoto, R. R., Li, S.-M., Katz, J. L., Fantegrossi, W. E. and Coop, A. (2011) Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug and Alcohol Dependence 118: 40-47. (PMID: 21410799)
Mesangeau, C., Amata, E., Alsharif, W., Seminerio, M. J., Robson, M. J., Matsumoto, R. R., Poupaert, J. H. and McCurdy, C. R. (2011) Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. European Journal of Medicinal Chemistry 46: 5154-5161. (PMID: 21899931)
Seminerio, M. J., Kaushal, N., Shakih, J., Huber, J., Coop, A. and Matsumoto, R. R. (2011) Sigma () receptor ligand AC927 attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacology Biochemistry and Behavior 98: 12-20. (PMID: 21130800)
Robson, M. J., Elliott, M., Seminerio, M. J. and Matsumoto, R. R. (2011) Evaluation of sigma receptors in the antidepressant-like effects of ketamine in vitro and in vivo. European Neuropsychopharmacology, Epub ahead of print. (PMID: 21911285)
Fishback, J. A., Robson, M. J., Xu, Y. T. and Matsumoto, R. R. (2010) Sigma receptors: new potential target for antidepressant drug discovery. Pharmacology and Therapeutics 127: 271-282. (PMID: 20438757)
Hsin, L.-W., Chang, L.-T., Rothman, R. B., Dersch, C. M., Fishback, J. A. and Matsumoto, R. R. (2010) Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinolines. Journal of Medicinal Chemistry 53: 1392-1396. (PMID: 20055417)
Maize, D. F., Fuller, S. H., Hritcko, P. M., Matsumoto, R. R., Soltis, D. A., Taheri, R. R. and Duncan, W. (2010) Remediation: a review of programs in pharmacy and other health professions. American Journal of Pharmaceutical Education 74: 25. (PMID: 20414438)
Stavitskaya, L., Seminerio, M. J., Matthews-Tsourounis, M., Matsumoto, R. R. and Coop, A. (2010) The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands. Bioorganic and Medicinal Chemistry Letters 20: 2564-2565. (PMID: 20338757)
Xu, Y. T., Kaushal, N., Shaikh, J., Wilson, L. L., Mesangeau, C., McCurdy, C. R. and Matsumoto, R. R. (2010) A novel substituted piperazine, 3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3H)-thione (CM156), attenuates the stimulant and toxic effects of cocaine in mice. Journal of Pharmacology and Experimental Therapeutics 333: 491-500. (PMID: 20100904)
“Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter,” U.S. application number 12/248,234, published as US 20090093513 A1
“Highly selective sigma receptor ligands,” International application number PCT/US08/73478, U.S. application number 60/956,249, filed August 18, 2008
“Highly selective sigma receptor ligands,” serial number 12/785,217, filed May 21, 2010
1992-1996 Assistant Professor in Residence
Dept. of Neurology, University of California Irvine, Irvine, CA
1996-2001 Assistant Professor
Dept. of Pharmacology & Toxicology, Univ. of Oklahoma HSC, OK City, OK
2001-2004 Associate Professor and Edith Gaylord Harper Presidential Professor
Dept. of Pharmaceutical Sciences, Univ. of Oklahoma HSC, Oklahoma City, OK
2004-2005 Associate Professor
Dept. of Pharmacology, University of Mississippi, Oxford, MS
Dept. of Pharmacology, University of Mississippi, Oxford, MS
2008-present Professor and Associate Dean for Research and Graduate Programs
Dept. of Basic Pharmaceutical Sciences, West Virginia Univ., Morgantown, WV
Introduction to Research, School of Pharmacy
Pharmacy as a Profession, School of Pharmacy
Pharmaceutical Investigations, School of Pharmacy
Area of Emphasis in Research, School of Pharmacy
Research, Graduate Program in Pharmaceutical and Pharmacological Sciences (PPS)
Dissertation Research, Graduate Program in PPS
Advanced Pharmacology, Graduate Program in PPS
Neuroscience Topics, Graduate Program in Neuroscience
Drug Discovery Elective, Graduate Program in PPS
NIH study sections (past five years): NIDA-L “Medications Development Research Subcommittee,” National Institute on Drug Abuse Initial Review Group, regular member (2004-2009); Special emphasis review panel for NIH, “NIDA-L conflicts review panel,” (2005-2009); NOI DA-07-8872 special emphasis review panel for National Institute on Drug Abuse, NIH, “Rodent drug discrimination and locomotor activity” (2007); RFA-AT-07-003 special emphasis review panel for National Center for Complementary and Alternative Medicine, NIH, “Tools and technology to measure patient adherence in CAM research: Phase II limited competition (SBIR R44)” (2007); Special emphasis review panel for NIH, “International brain disorders” (2007); Special emphasis review panel for NIH, “International cooperative biodiversity groups (ICBG)” (2008); Chair of special emphasis review panel for National Institute on Drug Abuse, NIH, “NIDA-L conflicts review panel,” (2008); RFA DA09-001 special emphasis review panel for National Institute on Drug Abuse, NIH, “Medication development for cannabis-related disorders” (2008-2009); PAR-09-011 special emphasis review panel for National Institute on Drug Abuse, NIH, “Diversity promoting institutions drug abuse research program (R24)” (2009); RFA-GM-09-008 special emphasis review panel for NIMH/NIH, “Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)” (2009); PAR-08-238 special emphasis review panel for NIMH/NIH, “National Cooperative Drug Discovery and Development Groups” (2010, 2011); RFA-GM-10-009 special emphasis review panel for NINDS/NIH, “Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)” (2010); RFA-DA-10-013 special emphasis review panel for NIDA/NIH, “Translational Avant Garde Award for Medication Development for Diseases of Addiction,” (2010); RFA-GM-11-003 special emphasis review panel for NIMH/NIH, “Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)” (2011); RFA-DA-11-012 special emphasis review panel for NIDA/NIH, “Exploring Human Induced Pluripotent Stem Cells for Substance Abuse Research” (2011)
Editorial board: TheScientificWorldJOURNAL (Pharmacology domain)
American Association of Colleges of Pharmacy
American Society for Pharmacology and Experimental Therapeutics
College on Problems of Drug Dependence
International Drug Abuse Research Society
Society for Neuroscience